Endocarditis, Bacterial Clinical Trial
Official title:
Open Label Study to Assess the Efficacy and Safety of Daptomycin in Combination With Anti-Cell Wall Active Therapy in the Treatment of Enterococcal Endocarditis
The aim of this study is to determine the safety and efficacy of daptomycin when used as an
adjuvant agent to standard care in the treatment of proven native valve Enterococcal
endocarditis. Patients with this disease will be offered the option of receiving daptomycin
at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already
receiving. The hypothesis of this study is that daptomycin added to standard therapy for
Enterococcal endocarditis is safe and efficacious.
Patients who receive daptomycin + standard therapy will be compared to patients who receive
standard therapy alone with respect to the following outcomes:
1. Safety.
1. The frequency of any Grade 3 or 4 toxicity (DAIDS scale) will be measured.
2. The frequency of muscle toxicity or renal toxicity, as determined by predefined
criteria.
2. Efficacy.
1. Clinical efficacy.
- Time to clearance of bacteremia
- Cure at 6 weeks following completion of antibiotic therapy
- Mortality at 6 weeks following completion of antibiotic therapy
2. Microbiologic efficacy.
- Peak and trough serum bactericidal titers
- The minimum bactericidal concentration of Enterococci to daptomycin
We expect to enroll 40 patients over 2 years.
Status | Terminated |
Enrollment | 6 |
Est. completion date | October 2008 |
Est. primary completion date | October 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age 18 or over - Definite Enterococcal endocarditis, as defined by modified Duke criteria - Able to complete follow-up 3 and 6 weeks following completion of intravenous antibiotic therapy Exclusion Criteria: - Pregnancy or breast feeding - Creatine phosphokinase levels over two times the upper limit of normal - Renal insufficiency or dialysis requirement. - Presence of chronic indwelling bloodstream catheters or foreign body devices suspected as primary or secondary sites of enterococcal infection unamenable to removal or replacement - Inability to discontinue or abstain from use of a HMG CoA reductase inhibitor during the study period. - Hypersensitivity to any of the study medications. - Any condition that, in the investigator's opinion, may interfere with protocol compliance including, but not limited to, active substance abuse and/or dementia. - Prosthetic valve endocarditis |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | NewYork-Presbyterian Hospital, Weill Cornell Campus | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Weill Medical College of Cornell University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | frequency of any Grade 3 or 4 toxicity (DAIDS scale) | weekly | Yes | |
Primary | frequency of muscle toxicity or renal toxicity, as determined by predefined criteria | weekly | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00695903 -
Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia
|
Phase 2 | |
Recruiting |
NCT05644990 -
T2MR PCR Detection of ESKAPE Pathogens in Patients With Pyogenic Spondylodiscitis and Infective Endocarditis
|
||
Recruiting |
NCT04840225 -
Anemia in Patients With Endocarditis
|
||
Completed |
NCT00524212 -
How to Improve Diagnosis in Infective Endocarditis
|
N/A | |
Completed |
NCT03048643 -
Combining Opioid Addiction Treatment Services With CARe for Infectious Endocarditis
|
N/A | |
Completed |
NCT00144885 -
IMAGE-Endocarditis: Resonance Magnetic Imaging at the Acute Phase of Endocarditis
|
N/A | |
Completed |
NCT03306225 -
Characterization of Endocarditis to Streptococci and Impact of the CMI on the Future of the Patients
|
||
Active, not recruiting |
NCT05522764 -
Predictors of Infective Endocarditis Among Patients Managed for Staphylococcus Aureus Bacteremia, Particularly Staphylococcus Aureus Bacteriuria, and Time to Blood Culture Positivity
|
||
Terminated |
NCT04222257 -
Short-course Antibiotic Treatment in Gram-positive Cocci Infective Endocarditis
|
Phase 4 | |
Not yet recruiting |
NCT05152225 -
Neurological Complication of Infective Endocarditis: A Prospective Multi-site Cohort Study
|
||
Not yet recruiting |
NCT05613933 -
Effectiveness of Antibiotic Prophylaxis of Infective Endocarditis for Invasive Dental Procedures in Patients With Prosthetic Heart Valves and/or History of Infective Endocarditis
|
N/A | |
Recruiting |
NCT02979951 -
Fosfomycin i.v. for Treatment of Severely Infected Patients
|
||
Active, not recruiting |
NCT06434012 -
Barts Endocarditis Research Registry
|
||
Recruiting |
NCT06250985 -
New Treatment of Cardiac Device Infections; Immediate Reimplantation After Removal of Infected System
|
Phase 3 |